Marcin Mardas1,2, Marta Stelmach-Mardas3,4, Radosław Madry1. 1. Department of Oncology, Poznan University of Medical Sciences, Szamarzewskiego Str 82/84, 60-569, Poznan, Poland. 2. Department of Human Nutrition and Hygiene, Poznan University of Life Science, Wojska Polskiego Str 28, 60-637, Poznan, Poland. 3. Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Arthur-Scheunert Allee 114-116, 14558, Nuthetal, Germany. stelmach@dife.de. 4. Department of Pediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Sciences, Szpitalna Str 27/33, 60-572, Poznan, Poland. stelmach@dife.de.
Abstract
PURPOSE: The aim of this study was to evaluate whether body weight changes in patients undergoing chemotherapy for epithelial ovarian cancer (EOC) influence progression-free survival (PFS) and overall survival (OS). METHODS: An analysis of 190 patients diagnosed with ovarian cancer after first-line chemotherapy was conducted. Changes in body weight were assessed by comparing measurements at baseline to those of the third and sixth cycles of chemotherapy. PFS and OS were calculated with the Kaplan-Meier method and multivariate Cox model. RESULTS: Significant reduction in body weight in advanced EOC was observed with no changes in early EOC. Significant differences in PFS were observed in advanced EOC patients that lost more than 5 % of their body weight (6 months), maintained weight (13 months), or gained more than 5 % of their body weight (15 months). Similarly, significant differences in OS were noted in advanced EOC at the following time points: 24.3, 42.4, and 66.2 months. No effect was reported for early EOC patients. The multivariate Cox analysis showed significant body weight changes from the first to the sixth chemotherapy cycle for PFS (HR = 0.97; 95 % CI 0.95-0.99) and OS (HR = 0.94; 95 % CI 0.91-0.97) as well as from the first to the third chemotherapy cycle for OS (HR = 0.93; 95 % CI 0.88-0.98). CONCLUSIONS: Body weight changes can be recognized as a prognostic factor for PFS and OS in advanced EOC patients undergoing chemotherapy. Weight loss is associated with poorer survival while weight gain improved outcomes.
PURPOSE: The aim of this study was to evaluate whether body weight changes in patients undergoing chemotherapy for epithelial ovarian cancer (EOC) influence progression-free survival (PFS) and overall survival (OS). METHODS: An analysis of 190 patients diagnosed with ovarian cancer after first-line chemotherapy was conducted. Changes in body weight were assessed by comparing measurements at baseline to those of the third and sixth cycles of chemotherapy. PFS and OS were calculated with the Kaplan-Meier method and multivariate Cox model. RESULTS: Significant reduction in body weight in advanced EOC was observed with no changes in early EOC. Significant differences in PFS were observed in advanced EOC patients that lost more than 5 % of their body weight (6 months), maintained weight (13 months), or gained more than 5 % of their body weight (15 months). Similarly, significant differences in OS were noted in advanced EOC at the following time points: 24.3, 42.4, and 66.2 months. No effect was reported for early EOC patients. The multivariate Cox analysis showed significant body weight changes from the first to the sixth chemotherapy cycle for PFS (HR = 0.97; 95 % CI 0.95-0.99) and OS (HR = 0.94; 95 % CI 0.91-0.97) as well as from the first to the third chemotherapy cycle for OS (HR = 0.93; 95 % CI 0.88-0.98). CONCLUSIONS: Body weight changes can be recognized as a prognostic factor for PFS and OS in advanced EOC patients undergoing chemotherapy. Weight loss is associated with poorer survival while weight gain improved outcomes.
Entities:
Keywords:
Body mass; Ovarian cancer; Prognostic factor; Survival
Authors: Karen M Gil; Heidi E Frasure; Michael P Hopkins; Eric L Jenison; Vivian E von Gruenigen Journal: Gynecol Oncol Date: 2006-05-11 Impact factor: 5.482
Authors: Z Malihi; M Kandiah; Y M Chan; M Esfandbod; M Vakili; M Hosseinzadeh; M Zarif Yeganeh Journal: Eur J Cancer Care (Engl) Date: 2014-10-30 Impact factor: 2.520
Authors: Anlan Cao; Brenda Cartmel; Fang-Yong Li; Linda T Gottlieb; Maura Harrigan; Jennifer A Ligibel; Radhika Gogoi; Peter E Schwartz; Melinda L Irwin; Leah M Ferrucci Journal: J Cancer Surviv Date: 2022-04-04 Impact factor: 4.062
Authors: Stephanie Stelten; Christelle Schofield; Yvonne A W Hartman; Pedro Lopez; Gemma G Kenter; Robert U Newton; Daniel A Galvão; Meeke Hoedjes; Dennis R Taaffe; Luc R C W van Lonkhuijzen; Carolyn McIntyre; Laurien M Buffart Journal: Cancers (Basel) Date: 2022-09-20 Impact factor: 6.575
Authors: Stephanie Stelten; Meeke Hoedjes; Gemma G Kenter; Ellen Kampman; Rosalie J Huijsmans; Luc Rcw van Lonkhuijzen; L M Buffart Journal: BMJ Open Date: 2020-11-04 Impact factor: 2.692